ABOUT PHOSPLATIN THERAPEUTICS
Phosplatin Therapeutics is a clinical stage pharmaceutical company FOunded by two entrepreneurs, based on over twenty years of work by the inventor. We are currently developing phosphaplatins, a family of rationally designed small-molecule agents for the treatment of cancer.
The lead agent, PT-112, is a first-in-class conjugate of pyrophosphate and platinum that combines apoptotic and immunogenic properties in combating cancer, along with an exceptional tolerability profile. It was rationally designed to avoid the toxicity and drug resistance mechanisms common to conventional chemotherapy. Because of its unique properties, PT-112 is being investigated in both solid tumors and hematological malignancies.
Since inception, the company has built a robust program through a variety of investigations of these novel compounds. Our collaborations with pharmaceutical partners, universities and contract research organizations range across thirteen countries.
The ongoing Phase I study of PT-112 is led by the investigational cancer therapeutics group at the MD Anderson Cancer Center in Houston, Texas, along with three other U.S. sites, and was the subject of a presentation and peer-review poster discussion at the asco 2017 annual meeting.
Under a collaborative agreement with SciClone Pharmaceuticals for rights in greater China, PT-112 is also the subject of a Phase i / ii combination study ongoing in taiwan.
Our aim is to develop safe, effective and impactful new therapies for cancer patients around the world, and to create a vital and mission-driven enterprise based on the talent and drive of a team culture.
To learn more about us, please enjoy the video below: